EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%

Basit Öğe Kaydı
dc.authoridMUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridSEZER, AHMET/0000-0002-6445-1439;
dc.authorwosidMUSTAFA, ÖZGÜROĞLU/A-8234-2016
dc.authorwosidKilickap, Saadettin/AAP-3732-2021
dc.authorwosidSEZER, AHMET/AAD-2667-2020
dc.authorwosidZavizion, Viktor/C-2550-2019
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.contributor.authorSezer, A.
dc.contributor.authorKilickap, S.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.date.accessioned2024-06-12T11:20:21Z
dc.date.available2024-06-12T11:20:21Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.descriptionESMO Virtual Congress -- SEP 19-OCT 18, 2020 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofien_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc. and Sanofi.en_US
dc.identifier.doi10.1016/j.annonc.2020.08.2285
dc.identifier.endpageS1183en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1182en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.08.2285
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25573
dc.identifier.volume31en_US
dc.identifier.wosWOS:000573469102683en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleEMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu